Objectives

After participating in this educational activity, attendees should be able to:
1| Evaluate the benefits and limitations of emerging lipid-lowering therapies (e.g., PCSK9 inhibitors, siRNA-based therapies) in clinical practice.
2| Develop stepwise, evidence-based treatment strategies for special populations, including diabetes and familial hypercholesterolemia.
3| Select appropriate pharmacologic therapies for dyslipidemia, including statins, nonstatin agents, and triglyceride-lowering therapies, based on patient-specific risk profiles.

Presenter(s): 

Prarthana Desai, MD
Fellow
Division of Endocrinology& Diabetes
 

NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Prarthana Desai, MD SpeakerNo relevant relationships with ineligible companies to discloseNo

 

Session date: 
05/05/2026 - 12:00pm to 1:00pm EDT
Location: 
Webinar
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category 1 CME credit
    Baystate Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PA’s should only claim credit commensurate with the extent of their participation.
  • 1.00 ACPE Contact Hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 IPCE Credit Hour(s)
Please login or register to take this course.